PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 5,149 Shares

09 Jan 2026, 00:21 by Michael Walen · The Markets Daily

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) CEO Matthew Klein sold 5,149 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $76.95, for a total value of $396,215.55. Following the transaction, the chief executive officer owned 399,983 shares of the company’s stock, valued at $30,778,691.85. The trade was a 1.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

PTC Therapeutics Price Performance

PTC Therapeutics stock traded down $0.39 during mid-day trading on Thursday, reaching $76.85. The stock had a trading volume of 1,625,361 shares, compared to its average volume of 1,684,365. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The company has a 50-day moving average price of $76.26 and a two-hundred day moving average price of $62.43. The company has a market capitalization of $6.17 billion, a price-to-earnings ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. PTC Therapeutics’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned ($1.39) EPS. On average, equities research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its position in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. lifted its stake in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 249 shares during the period. Comerica Bank boosted its holdings in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 469 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 310 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in PTC Therapeutics by 42.1% during the second quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 295 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a report on Thursday. Jefferies Financial Group increased their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. Finally, TD Cowen upped their target price on shares of PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $77.27.

Read Our Latest Stock Analysis on PTC Therapeutics

Key Headlines Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Recent fundamentals still supportive — PTC reported an earnings and revenue beat in its last quarter (Nov.) and maintains strong margins relative to peers, which underpins the stock’s valuation and analyst interest. MarketBeat PTCT profile
Neutral Sentiment: Small inducement grant: the company approved 300 restricted stock units for a new non‑executive employee on Jan. 2 — immaterial dilution and likely not a major near‑term driver. PR Newswire: Inducement Grants
Neutral Sentiment: Analyst consensus is a “Hold” with a mixed set of price targets and ratings — this produces limited conviction among buy‑side actors and can temper short‑term moves. Analyst consensus report
Negative Sentiment: Heavy insider selling disclosed in multiple Form 4s — several executives and directors (including the CEO, CFO, EVP, VPs and others) sold several tens of thousands of shares across Jan. 6–7 at ~\$77 per share, representing millions of dollars of proceeds. Collective insider sales at this scale can put near‑term downward pressure on the stock and signal to some investors that insiders are taking gains. The filings and aggregated alert are here for review. InsiderTrades: Jan. insider sales alert

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.